Drug news
BioAlliance files Sitavir in the EU for Orofacial Herpes
BioAlliance has filed its orofacial herpes drug Sitavir (aciclovir Lauriad) through the decentralised procedure in Austria, Denmark, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden and the UK, with Sweden acting as the reference member state. Sitavir is a mucoadhesive buccal tablet delivering high concentrations of the active ingredient to the mucosa and lips, the sites of the herpes infection, using BioAlliance's Lauriad delivery system.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.